title: Paranasal sinus tumors: Peter MacCallum Cancer Institute experience.
abstract: BACKGROUND
  The purpose of this study was to evaluate the local control, pattern of recurrence, overall survival, and prognostic factors of patients with squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma of the paranasal sinuses (PNS) and nasal cavity (NC) presenting to our center for curative treatment over a 10-year period.
  
  
  METHODS
  Between 1991 and 2000, 60 patients with SCC (n = 32), adenocarcinoma (n = 25), and undifferentiated carcinoma (n = 3) of the PNS or NC were identified. Forty patients received surgery and postoperative radiotherapy, four surgery alone; 11, radiotherapy alone; three radical radiotherapy after surgical recurrence; one, chemoradiotherapy and surgery; and one, induction chemotherapy followed by radiotherapy.
  
  
  RESULTS
  Forty-seven patients (78%) were seen with T3-4 disease; however, most (92%) were node negative on initial assessment. The predominant failure pattern was local disease persistence or recurrence. The estimated 2- and 5-year local control rates were 63% and 49%, respectively. Orbital and neural invasion significantly affected local control. The estimated 2- and 5 year overall survival rates were 57% and 40%, respectively.
  
  
  CONCLUSIONS
  Local failure remains the dominant cause for poor outcome in this group of patients. Because of the proximity of critical normal structures, the ability to perform adequate surgery and to deliver effective radiotherapy is limited in many cases. The use of postoperative concurrent chemoradiotherapy warrants further investigation.
authors.affiliation: Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria 3002, Australia. Sandro.Porceddu@petermac.org
authors.forename: Sandro
authors.initials: S
authors.lastname: Porceddu
authors.forename: Jarad
authors.initials: J
authors.lastname: Martin
authors.forename: Gowrie
authors.initials: G
authors.lastname: Shanker
authors.forename: LeAnn
authors.initials: L
authors.lastname: Weih
authors.forename: Christine
authors.initials: C
authors.lastname: Russell
authors.forename: Danny
authors.initials: D
authors.lastname: Rischin
authors.forename: June
authors.initials: J
authors.lastname: Corry
authors.forename: Lester
authors.initials: L
authors.lastname: Peters
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia / Q000453:epidemiology; D001766:Blindness / Q000209:etiology; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D009423:Nervous System Neoplasms / Q000556:secondary; D009669:Nose Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009918:Orbital Neoplasms / Q000556:secondary; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate